Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni, Fang Ye, Meng-Li Cheng, Yu Feng, Yong-Qiang Deng, Hui Zhao, Peng Wei, Jiwan Ge, Mengting Gou, Xiaoli Li, Lin Sun, Tianshu Cao, Pengzhi Wang, Chao Zhou, Rongrong Zhang, Peng Liang, Han Guo, Xinquan Wang, Cheng-Feng Qin, Fang Chen, Chen Dong, Ling Ni, Fang Ye, Meng-Li Cheng, Yu Feng, Yong-Qiang Deng, Hui Zhao, Peng Wei, Jiwan Ge, Mengting Gou, Xiaoli Li, Lin Sun, Tianshu Cao, Pengzhi Wang, Chao Zhou, Rongrong Zhang, Peng Liang, Han Guo, Xinquan Wang, Cheng-Feng Qin, Fang Chen, Chen Dong

Abstract

The World Health Organization has declared SARS-CoV-2 virus outbreak a worldwide pandemic. However, there is very limited understanding on the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested, 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells. Our work provides a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It also has implications in developing an effective vaccine to SARS-CoV-2 infection.

Keywords: COVID-19 patients; SARS-CoV-2; SARS-CoV-2-specific T cells; SARS-CoV-2-specific antibody; adaptive immunity.

Conflict of interest statement

Declaration of Interests L.N., Y.F., W.P., and C.D. have filed a provisional patent on the methodology of detecting SARS-CoV-2-specific antibody responses.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
SARS-CoV-2 NP- and S-RBD-Specific Antibodies in COVID-19 Convalescent Individuals (A) Titration of individual serum samples. (B) Serological responses of 14 COVID-19 patients to recombinant NP (top) and S-RBD (bottom). Dilution of 1:50 was used for IgM and 1:450 for IgG. (C) Data from the same experiments with (A) were presented as AUC. (D) IgG isotypes of 14 COVID-19 patients to recombinant NP and S-RBD. NP, nucleocapsid protein; S-RBD, receptor binding domain of spike protein; HD, healthy donor; Pt, patient; AUC, area under curve. The experiment was performed in duplicates. Date are presented as mean ± SEM. For HD 1–3, the sera were collected in 2018. For HD 4–6, the sera were from close contacts and collected in 2020. ∗p < 0.05, 0.05 < ∗∗p < 0.001, ∗∗∗p < 0.001.
Figure 2
Figure 2
Measurement of Neutralizing Antibody Titers in COVID-19 Convalescent Individuals (A) Correlation analysis of neutralizing antibody titers in COV1D-19 patients measured by pseudovirus and live SARS-CoV-2 (n = 20). (B) Neutralizing curves of 14 COVID-19 patients measured by pseudovirus-based assay. The experiment with patients was performed in triplicates. The experiment with healthy donors was performed in duplicates. (C) Measurement of neutralizing antibody titers of 14 COVID-19 patients by pseudovirus-based assay. (D) Correlation between NAT50 and AUC of anti-S-RBD (left) and anti-NP (right) IgG (n = 14). HD, healthy donor; Pt, patient; AUC, area under curve; NAT50, neutralizing antibody titers. Date are presented as mean ± SEM. ∗p < 0.05, 0.05 < ∗∗p < 0.001, ∗∗∗p < 0.001.
Figure 3
Figure 3
T cell Responses to Recombinant SARS-CoV-2 Proteins in COVID-19 Convalescent Individuals (A) Phenotypic analysis of PBMCs from representative COVID-19 patients. (B) Summarized data on the frequencies of different immune cell subsets in COVID-19 patients. HD, healthy donors (n = 2); D-Pt, discharged patients (n = 3); F-Pt, follow-up patients (n = 5). (C) IFN-γ ELISpot analysis of COVID-19 patients to recombinant proteins. The experiments were performed in duplicates. (D) Correlation analysis of the NAT50 and the numbers of NP-specific T cells (n = 14). M protease, main protease; NP, nucleocapsid protein; S-RBD, receptor binding domain of spike protein; NAT50, neutralizing antibody titers. Date are presented as mean ± SEM.

References

    1. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133:13–19.
    1. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
    1. Deng H.K., Unutmaz D., KewalRamani V.N., Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 1997;388:296–300.
    1. Di Pierro F., Bertuccioli A., Cavecchia I. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol. Dietol. 2020 doi: 10.23736/S1121-421X.20.02697-5. Published online March 12, 2020.
    1. Haveri A., Smura T., Kuivanen S., Österlund P., Hepojoki J., Ikonen N., Pitkäpaasi M., Blomqvist S., Rönkkö E., Kantele A. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25:16–21.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Ko J.H., Müller M.A., Seok H., Park G.E., Lee J.Y., Cho S.Y., Ha Y.E., Baek J.Y., Kim S.H., Kang J.M. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn. Microbiol. Infect. Dis. 2017;89:106–111.
    1. Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 doi: 10.1038/s41586-020-2180-5. Published online March 30, 2020.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
    1. Mahallawi W.H., Khabour O.F., Zhang Q., Makhdoum H.M., Suliman B.A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13.
    1. Nicholls J.M., Poon L.L., Lee K.C., Ng W.F., Lai S.T., Leung C.Y., Chu C.M., Hui P.K., Mak K.L., Lim W. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–1778.
    1. Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680–686.
    1. Phelan A.L., Katz R., Gostin L.O. Challenges for Global Health Governance. JAMA; China: 2020. The Novel Coronavirus Originating in Wuhan.
    1. Shi Y., Wan Z., Li L., Li P., Li C., Ma Q., Cao C. Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J. Clin. Virol. 2004;31:66–68.
    1. Thevarajan I., Nguyen T.H.O., Koutsakos M., Druce J., Caly L., van de Sandt C.E., Jia X., Nicholson S., Catton M., Cowie B. Breadth of Concomitant Immune Responses Prior to Patient Recovery: A Case Report of Non-Severe COVID-19. Nat. Med. 2020;26:453–455.
    1. Thiel V., Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19:121–132.
    1. Vijay R., Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. Curr. Opin. Virol. 2016;16:70–76.
    1. Wang W., Wang H., Deng Y., Song T., Lan J., Wu G., Ke C., Tan W. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg. Microbes Infect. 2016;5:e113.
    1. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
    1. Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 doi: 10.1038/s41586-020-2196-x. Published online April 1, 2020.
    1. Woo P.C., Lau S.K., Wong B.H., Tsoi H.W., Fung A.M., Chan K.H., Tam V.K., Peiris J.S., Yuen K.Y. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J. Clin. Microbiol. 2004;42:2306–2309.
    1. Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
    1. Xie S., Huang J., Qiao Q., Zang W., Hong S., Tan H., Dong C., Yang Z., Ni L. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol. Immunother. 2018;67:1685–1694.
    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit